Successful Treatment of Mucous Membrane Pemphigoid With Infliximab

Heffernan, Michael; Bentley, Danette D.

doi:10.1001/archderm.142.10.1268

Cited by 66 publications

(25 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current literature suggests that inflammation can be controlled with dapsone, 3 sulfasalazine, 4 or methotrexate 5 in mild to moderate disease; azathioprine 6 in moderate disease; cyclophosphamide 7,8 with prednisone at induction for moderate or severe active disease; intravenous immunoglobulin 9 for treatment failures; and tumor necrosis factor inhibitors [10][11][12] for treatment failures.…”

mentioning

confidence: 99%

Treatment of Mucous Membrane Pemphigoid With Mycophenolate Mofetil

Nottage

Hammersmith

Murchison

et al. 2013

Cornea

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Treatment of Mucous Membrane Pemphigoid With Mycophenolate Mofetil

Nottage

Hammersmith

Murchison

et al. 2013

Cornea

View full text Add to dashboard Cite

show abstract

“…In addition to conventional treatments, some biologic agents including rituximab,[2021] etanercept,[222324] infliximab,[25] and immunomodulatory agents, such as IVIg, have been reported to be effective in the treatment MMP.…”

Section: Methodsmentioning

confidence: 99%

The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature

Tavakolpour

2016

J Res Med Sci

View full text Add to dashboard Cite

Background:Mucous membrane pemphigoid (MMP) is considered an autoimmune blistering disease that predominantly affects mucous membranes. Various treatments are available for controlling the diseases, but not all of them may respond.Materials and Methods:PubMed and Google Scholar were searched for all the associated studies until 2015, using the keywords such as “cicatricial pemphigoid” or “ocular pemphigoid” or “mucous membrane pemphigoid” or “MMP” and “intravenous immunoglobulin” or “IVIg” to find all the relevant studies. The last search update was for September 2, 2015. Among the searched items, only English studies were included in the review.Results:After excluding nonrelevant studies, 13 studies with a total number of seventy patients with MMP who were under treatment with IVIg were analyzed. The 65 patients responded completely, one did not respond, two had partially responded, and the remaining two patients stopped IVIg therapy, which resulted in ocular cicatricial pemphigoid progression. Majority of the studies reported mild adverse effects while two of them did not report any unwanted side effect. The most common side effect was headache, followed by nausea. Most of the patients who had a cessation of IVIg therapy before achieving clinical remission experienced the disease progression.Conclusion:Overall, it can be concluded that IVIg therapy was very helpful in treatment of MMP patients who did not respond to conventional therapy or stopped using them for various side effects. Adverse effects associated with IVIg therapy were considerably lower than conventional therapy that can lead toward treatment with this agent in patients who suffer from severe side effects.

show abstract

“…Infliximab ist ein chimärer IgG1k-monoklonaler Antikörper, der die Bindung des Zytokins TNF-α an seinen Rezeptor inhibiert. In einem Fallbericht konnte bereits 2 Wochen nach initialer Gabe eine umfassende Stabilisierung erreicht werden [43].…”

Section: A) Tnf-α-antagonistenunclassified

Das okuläre vernarbende Pemphigoid - aktuelle Aspekte zu Klinik und Therapie einer problematischen Erkrankung

Rübsam

Klein

Pleyer

2013

Klin Monatsbl Augenheilkd

View full text Add to dashboard Cite

The ocular cicatricial pemphigoid (OCP) belongs to a family of chronically progressive autoimmune disorders, predominantly affecting mucous membranes (mucous membrane pemphigoids). It is an immunopathologically heterogeneous group of disorders with variable phenotypes that share the unique feature of a subepidermal blistering, through disruption of the adhesion between epidermis and dermis. A key feature is the chronically active inflammation with consecutive fibrosis, leading to a partial or complete loss of function of the affected organ. The ocular disease as a chronic cicatrising conjunctivitis is a common manifestation of the mucous membrane pemphigoid. The identification of the subtle pathology and the prompt initiation of an appropriate therapy are of pivotal importance. One purpose is to prevent further vision loss due to extensive corneal scarring and life-threatening systemic complications, such as the formation of oesophageal or tracheal strictures. So far there are no prospective, randomised studies, regarding the therapy guidelines with an evidence level more than III. The autoimmune nature of the disease implies that systemic immunosuppression is the only effective treatment option, most notably in extended stages. The aim of our study is to give a guideline for a stage adjusted therapy with conventional immunosuppressants and to give a perspective for alternative therapies, especially for recalcitrant disease.

show abstract

Successful Treatment of Mucous Membrane Pemphigoid With Infliximab

Cited by 66 publications

References 21 publications

Treatment of Mucous Membrane Pemphigoid With Mycophenolate Mofetil

Treatment of Mucous Membrane Pemphigoid With Mycophenolate Mofetil

The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature

Das okuläre vernarbende Pemphigoid - aktuelle Aspekte zu Klinik und Therapie einer problematischen Erkrankung

Contact Info

Product

Resources

About